Statins, Low-Density Lipoprotein Cholesterol, and Risk of Cancer
Alawi A. Alsheikh-Ali, MD*, ,
Thomas A. Trikalinos, MD*,
David M. Kent, MD, MS* and
Richard H. Karas, MD, PhD,*
* Institute for Clinical Research and Health Policy Studies, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
Molecular Cardiology Research Institute and Division of Cardiology, Department of Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Relationship Between On-Treatment LDL-C Levels and Incident Cancer in the Statin and Control Arms
Each arm from each trial is considered an independent cohort of statin-treated or control individuals and is represented by an empty circle (with size proportional to each arm's weight in the meta-regressions). Note how statin cohorts (arms) are shifted toward lower on-treatment low-density lipoprotein cholesterol (LDL-C) levels, while corresponding to the same range of incident cancer rates. Note the LDL-C scale on the horizontal axis.
|
|
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Risk of Cancer in Statin Versus Control Cohorts for Any Given Level of On-Treatment LDL-C
Each trial is represented by an empty circle (with size proportional to its weight in the meta-regressions). The slope of the regression line represents the extent to which the incidence rate ratio for cancer depends on the on-treatment low-density lipoprotein cholesterol (LDL-C) level in the statin arms (p = 0.73 for the effect of on-treatment LDL-C on the incidence rate ratio for cancer in statin vs. control cohorts). Note the LDL-C scale on the horizontal axis.
|
|
|
